Andra AP fonden Has $6.25 Million Stock Position in DexCom, Inc. $DXCM

Andra AP fonden raised its position in DexCom, Inc. (NASDAQ:DXCM) by 30,833.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,800 shares of the medical device company’s stock after buying an additional 92,500 shares during the period. Andra AP fonden’s holdings in DexCom were worth $6,245,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in DXCM. Twin Peaks Wealth Advisors LLC acquired a new position in shares of DexCom in the 2nd quarter worth approximately $26,000. SJS Investment Consulting Inc. increased its holdings in DexCom by 4,800.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after purchasing an additional 384 shares in the last quarter. Financial Consulate Inc. bought a new position in DexCom in the 3rd quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DexCom in the second quarter worth $45,000. Finally, Sound Income Strategies LLC boosted its stake in DexCom by 83.8% in the third quarter. Sound Income Strategies LLC now owns 625 shares of the medical device company’s stock worth $43,000 after purchasing an additional 285 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

DXCM stock opened at $73.43 on Friday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The firm has a market cap of $28.26 billion, a P/E ratio of 34.97, a P/E/G ratio of 1.43 and a beta of 1.49. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. The company’s 50-day moving average price is $70.24 and its two-hundred day moving average price is $69.15.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the prior year, the business earned $0.45 earnings per share. The business’s revenue for the quarter was up 13.1% compared to the same quarter last year. On average, analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several research reports. Morgan Stanley restated an “overweight” rating on shares of DexCom in a research report on Monday, January 12th. Truist Financial restated a “buy” rating and set a $80.00 target price (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Citigroup reissued a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Mizuho increased their target price on DexCom from $78.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, February 13th. Finally, Piper Sandler restated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $85.18.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.